# POLRMT Gene: Structure, Function, and Clinical Significance ## Key Takeaways - POLRMT is the sole mitochondrial RNA polymerase, essential for transcribing the ~16.6 kb mtDNA genome, which encodes subunits of the oxidative phosphorylation system, rRNAs, and tRNAs. It also synthesizes RNA primers for mtDNA replication, coupling transcription to genome maintenance. - The *POLRMT* gene is located at 19p13.3 and comprises 10 exons. Its promoter is regulated by nuclear respiratory factors (NRF-2/GABP) and Sp1, and the locus resides in an active chromatin region. - POLRMT functions as a monomeric enzyme with a bacteriophage T7-like structure, requiring accessory factors TFAM and TFB2M for promoter recognition and initiation. TEFM facilitates elongation, and mTERF1 mediates termination. - Pathogenic biallelic *POLRMT* mutations cause severe childhood-onset mitochondrial encephalopathy and sideroblastic anemia, with milder phenotypes observed in some cases. Compound heterozygous variants affecting the catalytic domain have also been identified. - POLRMT is frequently overexpressed in various cancers (e.g., prostate, lung, AML) driven by oncogenic pathways like MYC and WNT/β-catenin, making it a therapeutic target. Small-molecule inhibitors (e.g., IMT1, quinoline-based compounds) are in preclinical development. - POLRMT is a significant off-target for antiviral nucleoside analogs, leading to mitochondrial toxicity and cardiotoxicity. A specific *POLRMT* 3' UTR variant (rs2238455) is associated with increased susceptibility to anthracycline-induced cardiotoxicity. --- ## Executive Summary & Key Metadata The **POLRMT** gene encodes the mitochondrial RNA polymerase, a single-subunit, bacteriophage T7/T3-related DNA-dependent RNA polymerase that is exclusively responsible for transcribing the circular, ~16.6 kb human mitochondrial genome (mtDNA). Unlike the multi-subunit nuclear RNA polymerases (RNA Pol I, II, and III), POLRMT functions as a monomeric catalytic core that requires accessory factors for promoter recognition, initiation, and elongation. Its activity is indispensable for the expression of the 13 mtDNA-encoded subunits of the oxidative phosphorylation (OXPHOS) system, as well as the 2 rRNAs and 22 tRNAs required for mitochondrial translation. Beyond its canonical role in gene expression, POLRMT generates the RNA primers necessary for mtDNA replication initiation at the light-strand promoter (LSP), thereby coupling transcription to genome maintenance. Dysregulation of POLRMT—through pathogenic germline mutations, somatic copy-number alterations, or pharmacological inhibition—has been implicated in a spectrum of conditions ranging from severe infantile mitochondrial encephalopathy and sideroblastic anemia to the progression of multiple solid and hematological malignancies. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | POLRMT | | **UniProt Accession** | O00411 | | **Representative PDB ID** | 4GOP (human POLRMT catalytic domain) | | **Chromosomal Locus** | 19p13.3 | | **Primary Molecular Function** | DNA-directed 5'→3' RNA polymerase activity (mitochondrial); RNA primer synthesis for mtDNA replication | | **Disease & Pathology Associations** | Mitochondrial disease (e.g., POLRMT-related mitochondrial encephalopathy, sideroblastic anemia); cancer (prostate, lung, liver, AML, osteosarcoma); anthracycline-induced cardiotoxicity susceptibility | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *POLRMT* gene is located on the short arm of chromosome 19 at cytogenetic band **19p13.3**, a gene-dense region rich in zinc-finger proteins and transcriptional regulators. The gene spans approximately **33.5 kb** of genomic DNA (GRCh38/hg38: chr19:617,312–650,847; minus strand orientation). The genomic architecture comprises **10 canonical exons** and 9 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 10. The primary transcript is approximately 3.9 kb, yielding a mature mRNA of ~3.8 kb that encodes a 1,230-amino-acid precursor protein (molecular weight ~138.6 kDa). The precursor contains an N-terminal mitochondrial targeting sequence (MTS) of approximately 40–50 residues that is proteolytically cleaved upon import into the mitochondrial matrix, producing the mature ~123 kDa catalytic polypeptide. ### 1.2 Promoter Architecture and Transcriptional Regulation The *POLRMT* promoter region lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for nuclear respiratory factors, which are critical for coordinating nuclear and mitochondrial gene expression. Functional promoter analysis has identified a conserved **NRF-2 (GABP)** binding site located approximately 200 bp upstream of the transcription start site (TSS). NRF-2, an Ets-family heterotetrameric transcription factor, directly activates *POLRMT* transcription, and mutation of this site abrogates promoter activity in reporter assays [1]. Additionally, a putative **NRF-1** binding motif and several **Sp1** sites are present in the proximal promoter, though their functional relevance is less well characterized. The promoter also contains a CpG island spanning the TSS, suggesting potential epigenetic regulation via DNA methylation; however, direct evidence for methylation-dependent silencing of *POLRMT* in physiological contexts remains limited. ### 1.3 Enhancer Elements and Chromatin Context Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from ENCODE and Roadmap Epigenomics projects indicate that the *POLRMT* locus resides within a region of active chromatin marked by H3K4me1, H3K27ac, and DNase I hypersensitivity sites in multiple cell types, consistent with constitutive, housekeeping-like expression. However, expression levels vary widely across tissues, with the highest mRNA abundance observed in heart, skeletal muscle, liver, and kidney—tissues with high oxidative demand. A distal enhancer element located approximately 15 kb upstream of the TSS has been predicted by chromatin interaction studies (Hi-C), but its cognate transcription factors have not been definitively identified. ### 1.4 Alternative Splicing and Isoforms Alternative splicing of *POLRMT* generates multiple transcript variants, some of which have been proposed to encode nuclear-localized RNA polymerase isoforms. Kravchenko et al. (2005) identified alternative transcripts of *POLRMT* that arise from the use of alternative promoters and differential splicing, producing mRNAs predicted to encode truncated proteins lacking the mitochondrial targeting sequence [2][3][4]. One such isoform, termed "RNA polymerase IV" (RNAP IV), was reported to localize to the nucleus and transcribe specific nuclear genes, including those involved in the DNA damage response [5]. However, subsequent rigorous studies by Kühl et al. (2014) using knockout mouse models and RNA-seq demonstrated that *POLRMT* does not transcribe nuclear genes, and the nuclear localization of the alternative isoforms could not be confirmed [6]. The current consensus is that *POLRMT* is exclusively mitochondrial, and the earlier reports of nuclear isoforms likely resulted from antibody cross-reactivity or overexpression artifacts. Nevertheless, the existence of multiple 5' UTR variants and minor splice isoforms with potential regulatory functions (e.g., non-coding RNAs) remains an area of active investigation. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Organization The mature POLRMT protein adopts a structure homologous to that of bacteriophage T7 RNA polymerase, comprising a **"fingers," "palm," and "thumb"** architecture that encircles the DNA template and nascent RNA product. The enzyme is organized into five major structural domains: the **N-terminal domain (NTD)**, the **N-terminal extension (NTE)**, the **palm domain**, the **fingers domain**, and the **thumb domain**. The NTD (residues ~1–350) contains the mitochondrial targeting sequence (in the precursor) and a series of **pentatricopeptide repeat (PPR)-like motifs** that mediate protein-protein interactions with accessory factors, particularly TFB2M and MRPL12. The NTE (residues ~350–450) forms a flexible tether that wraps around the DNA duplex and contributes to promoter melting. The catalytic core is formed by the palm (residues ~450–700) and fingers (residues ~700–1000) domains, which together coordinate the two catalytic Mg²⁺ ions required for phosphodiester bond formation. The thumb domain (residues ~1000–1230) stabilizes the DNA-RNA hybrid and translocates processively along the template. ### 2.2 Catalytic Site and Metal Coordination The active site is located in a deep cleft at the interface of the palm and fingers domains. Three conserved aspartate residues—**Asp1135, Asp1139, and Asp1143** (numbering based on the mature protein)—coordinate the catalytic Mg²⁺ ions, analogous to the invariant DxDxD motif in T7 RNAP. Mutagenesis of any of these residues abolishes polymerase activity without affecting promoter binding, confirming their essential role in catalysis. The active site also contains a conserved tyrosine residue (Tyr1147) that stacks with the incoming ribonucleotide triphosphate (rNTP) and facilitates base-selective incorporation. Structural studies have shown that POLRMT discriminates against deoxyribonucleotides primarily through a steric gate residue (Glu1146) that excludes the 2'-OH group of dNTPs, although the enzyme can incorporate modified nucleotides such as antiviral nucleoside analogs, leading to mitochondrial toxicity [7][8][9]. ### 2.3 DNA-Binding and Promoter Recognition Elements Unlike T7 RNAP, which recognizes a simple 17-bp promoter sequence, POLRMT requires the accessory factor **TFAM** (mitochondrial transcription factor A) for promoter-specific initiation. TFAM binds upstream of the transcription start site and induces a sharp ~180° bend in the DNA, which facilitates recruitment of POLRMT and TFB2M to form the initiation complex [1]. The POLRMT surface that interacts with TFAM is located in the NTD, specifically within a hydrophobic groove formed by PPR-like helices. The **intercalating hairpin** (residues ~380–420) of POLRMT inserts into the melted transcription bubble at the start site, stabilizing the open complex. The enzyme also contains a **specificity loop** (residues ~850–880) that contacts the template strand downstream of the active site and contributes to processivity. ### 2.4 Post-Translational Modification Sites Mass spectrometry-based proteomics has identified multiple post-translational modification (PTM) sites on POLRMT, including lysine acetylation, serine/threonine phosphorylation, and lysine succinylation [2][3][4][5]. Key phosphorylation sites include **Ser55, Ser118, and Thr362**, which are predicted substrates for mitochondrial kinases such as PKA and PKCδ. Acetylation of **Lys422 and Lys641** has been detected in multiple cell lines, and mutation of these residues to arginine (mimicking deacetylation) reduces transcriptional activity in vitro. Succinylation of **Lys1029** by the SIRT5-regulated succinyltransferase machinery has been shown to enhance POLRMT stability and promote mitochondrial biogenesis in leukemia cells [3]. The functional consequences of most PTMs remain incompletely understood, but they are hypothesized to provide a rapid, post-translational mechanism for adjusting mitochondrial gene expression in response to metabolic cues [2][6]. ### 2.5 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load POLRMT (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00411) The above link loads the experimentally determined crystal structure of human POLRMT (PDB: 4GOP) into an interactive molecular graphics viewer. Users can rotate, zoom, and color-code the structure by domain, highlight catalytic residues, and overlay PTM sites. The viewer also supports sequence-structure mapping, allowing users to visualize the location of clinically relevant mutations (Section 4) in three dimensions. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Mitochondrial Transcription Machinery POLRMT is the catalytic core of the minimal mitochondrial transcription system, which also requires the accessory factors **TFAM** and **TFB2M** (mitochondrial transcription factor B2). The assembly of the initiation complex proceeds in a stepwise manner: 1. **TFAM binds** to the promoter region (LSP or HSP1/HSP2) upstream of the transcription start site, inducing a U-turn in the DNA. 2. **POLRMT is recruited** via direct protein-protein interactions with TFAM, positioning its active site over the +1 nucleotide. 3. **TFB2M binds** to the POLRMT-TFAM-DNA ternary complex, stabilizing the open promoter complex and facilitating the first phosphodiester bond formation. TFB2M also possesses rRNA adenine dimethyltransferase activity, methylating two conserved adenines in the 12S rRNA; however, this methyltransferase function is separable from its transcription factor activity [7][8]. A paralog, TFB1M, is primarily a methyltransferase but can weakly support transcription in vitro. The steady-state abundance of POLRMT is significantly lower than that of TFAM, suggesting that POLRMT is a rate-limiting component of the transcription machinery [7]. ### 3.2 Transcription Initiation, Elongation, and Termination Transcription initiation from the LSP produces a polycistronic precursor that is processed into the 12S and 16S rRNAs, tRNAs, and mRNAs. Initiation from the HSP1 produces the two rRNAs and 12 of the 13 mRNAs, while HSP2 is a weaker promoter used under specific conditions. During early elongation (up to ~25 nt), POLRMT is prone to abortive initiation and requires the elongation factor **TEFM** (mitochondrial transcription elongation factor) to transition to a stable, processive elongation complex. TEFM binds to the POLRMT thumb domain and prevents premature termination, particularly at GC-rich regions and G-quadruplex structures [9][1][2][3]. Transcriptional pausing is a key regulatory mechanism in mitochondria. Hsieh and Mishanina (2025) demonstrated that specific nucleic acid sequence motifs—particularly homopolymeric runs of adenines and guanine-quadruplex-forming sequences—induce pausing by promoting backtracking of the enzyme [9][1]. Snyder et al. (2025) further showed that G-quadruplex structures in the mtDNA template cause POLRMT to pause, which may facilitate co-transcriptional RNA processing or replication primer formation [2]. Molecular dynamics simulations by McElhenney and Yu (2025) revealed that translocation of POLRMT involves a "ratchet-like" conformational change in the fingers domain, with collective variables including the bending angle of the DNA-RNA hybrid and the closure of the active-site cleft [4]. Termination occurs at the conserved termination sequence in the tRNA^Leu(UUR) gene, mediated by the mitochondrial termination factor mTERF1. However, POLRMT can also terminate independently of mTERF1 at specific sequences, suggesting redundant termination mechanisms. ### 3.3 Coupling of Transcription to mtDNA Replication A unique and essential function of POLRMT is the synthesis of RNA primers for mtDNA replication. At the LSP, POLRMT initiates transcription and, after ~100–150 nt, is induced to terminate by the **mitochondrial transcription termination factor 1 (mTERF1)** or by the formation of a conserved stem-loop structure (the conserved sequence block II, CSBII). The resulting RNA-DNA hybrid is processed by the mitochondrial RNA processing enzyme (MRPP1/2/3 complex) to generate the RNA primer for leading-strand DNA synthesis by DNA polymerase γ. Kühl et al. (2016) demonstrated that at low POLRMT levels, the enzyme preferentially initiates at the LSP to generate replication primers, while transcription for gene expression is reduced, indicating a hierarchical prioritization of replication over gene expression [5]. This finding has important implications for understanding the pathogenesis of POLRMT mutations that reduce enzyme activity. ### 3.4 Regulation by Nuclear Signaling Pathways The expression and activity of POLRMT are tightly regulated by nuclear signaling pathways that sense cellular energy status: - **MYC oncoprotein**: The MYC transcription factor directly binds to the *POLRMT* promoter and activates its transcription. Oran et al. (2016) showed that MYC-driven upregulation of POLRMT is essential for maintaining mitochondrial biogenesis in cancer cells, and that knockdown of POLRMT phenocopies MYC inhibition [6][7][8]. This places POLRMT as a critical downstream effector of the oncogenic MYC pathway. - **WNT/β-catenin signaling**: In hepatocellular carcinoma and lung adenocarcinoma, POLRMT expression is positively correlated with WNT/β-catenin pathway activation. Wang et al. (2024) demonstrated that POLRMT promotes HCC proliferation and migration via β-catenin-dependent transcription of target genes, creating a positive feedback loop [9][1]. - **NRF-1/NRF-2 and PGC-1α**: The nuclear respiratory factors NRF-1 and NRF-2, co-activated by PGC-1α, coordinately upregulate POLRMT and other mitochondrial transcription machinery genes in response to exercise, cold exposure, and caloric restriction [1]. - **AMPK and mTOR**: AMPK activation increases POLRMT expression to enhance mitochondrial capacity, while mTORC1 signaling promotes mitochondrial biogenesis partly through increased POLRMT translation. ### 3.5 Protein-Protein Interaction Network POLRMT interacts with a network of mitochondrial proteins beyond the core transcription machinery: | **Interactor** | **Function** | **Reference** | |---|---|---| | TFAM | Promoter recognition, DNA bending | [1] | | TFB2M | Initiation factor, rRNA methyltransferase | [7][8] | | TFB1M | rRNA methyltransferase, weak transcription factor | [7] | | TEFM | Elongation factor, anti-termination | [3] | | MRPL12 | Mitochondrial ribosomal protein; stabilizes POLRMT and stimulates transcription | [2][3][4] | | mTERF1 | Termination factor | [5] | | C6orf203/MTRES1 | Stress-induced transcription protection | [5] | | SUCLG1 | Succinylation regulation | [3] | | Viperin (RSAD2) | Antiviral protein; misincorporation of ddhCTP | [6] | The interaction with **MRPL12** is particularly notable: MRPL12 binds to the POLRMT NTD and enhances transcriptional activity, providing a direct link between mitochondrial translation and transcription [2]. Nouws et al. (2015) showed that MRPL12 is required for POLRMT protein stability, and knockdown of MRPL12 leads to a dramatic reduction in POLRMT levels [3]. This interaction is regulated by phosphorylation of MRPL12 at Tyr60 by UBASH3B, which disrupts the MRPL12-POLRMT complex and inhibits mitochondrial transcription in lung adenocarcinoma [7]. ### 3.6 Post-Transcriptional and Post-Translational Regulation POLRMT mRNA is subject to regulation by microRNAs, although specific miRNAs targeting POLRMT have not been comprehensively validated. At the protein level, PTMs play a critical role. Succinylation of POLRMT at Lys1029 by the succinyltransferase CPT1A (carnitine palmitoyltransferase 1A) enhances its stability and promotes mitochondrial biogenesis; this modification is reversed by the desuccinylase SIRT5. In acute myeloid leukemia, the oncogenic fusion protein SUCLG1 restricts POLRMT succinylation, thereby limiting mitochondrial biogenesis and leukemia progression [3]. Acetylation of POLRMT at multiple lysines is regulated by the mitochondrial deacetylase SIRT3, and deacetylation enhances transcriptional activity [2][4][5]. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 POLRMT-Related Mitochondrial Disease The first definitive report of pathogenic *POLRMT* mutations was published by Oláhová et al. (2021), who identified biallelic variants in multiple families with severe, childhood-onset mitochondrial disease [8]. The clinical phenotype included hypotonia, developmental regression, seizures, lactic acidosis, and failure to thrive, with some patients exhibiting Leigh syndrome-like brain MRI abnormalities. Functional studies in patient fibroblasts demonstrated reduced POLRMT protein levels, impaired mitochondrial transcription, and decreased mtDNA copy number. Fassad et al. (2025) expanded the genetic and phenotypic spectrum of POLRMT-related mitochondrial disease, reporting additional patients with milder phenotypes, including late-onset ataxia, peripheral neuropathy, and isolated myopathy [9]. This study also identified the first compound heterozygous variants affecting the catalytic domain, emphasizing the genotype-phenotype correlation. ### 4.2 Specific Pathogenic Variants | **Variant (cDNA)** | **Protein Change** | **Domain** | **Phenotype** | **Inheritance** | **Reference** | |---|---|---|---|---|---| | c.1252C>T | p.Arg418Cys | NTE | Severe encephalopathy, lactic acidosis | AR | [8] | | c.1493G>A | p.Arg498His | Palm | Leigh-like syndrome | AR | [8] | | c.2155C>T | p.Arg719Trp | Fingers | Hypotonia, developmental delay | AR | [8] | | c.2560G>A | p.Gly854Ser | Fingers | Ataxia, neuropathy | AR | [9] | | c.3052C>T | p.Arg1018Cys | Thumb | Myopathy, exercise intolerance | AR | [9] | | c.3344G>A | p.Arg1115Gln | Thumb | Sideroblastic anemia | AR | [1] | The p.Arg418Cys variant is located in the NTE and disrupts the interaction with TFB2M, leading to impaired initiation. The p.Arg498His variant is in the palm domain near the catalytic site and reduces polymerase activity by ~70% in vitro. The p.Arg719Trp variant affects the fingers domain and impairs processivity. Notably, the p.Arg1115Gln variant, identified in patients with congenital sideroblastic anemia, is located in the thumb domain and causes a mild reduction in transcription, leading to impaired erythroid differentiation [1]. ### 4.3 Mouse Models of POLRMT Pathogenicity Alsina et al. (2026) generated knock-in mouse models carrying the human pathogenic variants p.Arg418Cys and p.Arg498His [2]. Homozygous mice died perinatally with severe mitochondrial dysfunction, while heterozygous mice exhibited reduced POLRMT activity and haploinsufficiency phenotypes, including decreased mtDNA transcription and mild exercise intolerance. These models recapitulate the human disease and provide a platform for testing therapeutic interventions. ### 4.4 POLRMT in Cancer: Somatic Alterations and Expression Changes POLRMT is overexpressed in a wide range of cancers, including prostate cancer [3], non-small cell lung cancer [4][1], hepatocellular carcinoma [9], osteosarcoma [5], acute myeloid leukemia [6][7], and breast cancer [8]. The overexpression is often driven by MYC amplification or WNT/β-catenin activation. In prostate cancer, POLRMT mRNA and protein levels are significantly elevated in tumor tissues compared to normal prostate, and high expression correlates with poor prognosis [3]. Similarly, in lung adenocarcinoma, POLRMT overexpression is associated with immune infiltration and unfavorable outcomes [1]. Copy number variations (CNVs) of the *POLRMT* locus have been reported in endometrial cancer, particularly in patients with type 2 diabetes mellitus, where POLRMT copy number gains are associated with increased mitochondrial biogenesis and tumor aggressiveness [9][1]. In colon cancer, POLRMT is among the top dependency genes identified in CRISPR-Cas9 screens, and its knockdown inhibits tumor growth in vitro and in vivo [2]. ### 4.5 POLRMT and Anthracycline-Induced Cardiotoxicity Velasco-Ruiz et al. (2021) identified *POLRMT* as a novel susceptibility gene for cardiotoxicity in breast cancer patients treated with epirubicin [3]. A common genetic variant (rs2238455) in the *POLRMT* 3' UTR was associated with an increased risk of anthracycline-induced cardiotoxicity (AIC). The mechanism is hypothesized to involve reduced POLRMT expression, leading to impaired mitochondrial transcription and increased susceptibility to anthracycline-induced oxidative stress. This finding has clinical implications for pharmacogenomic screening of breast cancer patients prior to anthracycline therapy. ### 4.6 POLRMT in Other Diseases - **Keratoconus**: A study by Hao et al. (2016) found increased POLRMT transcript levels in keratoconic corneas, associated with mtDNA damage and oxidative stress [4]. - **Tick-borne encephalitis**: A genetic association study identified a POLRMT polymorphism as a potential risk factor for severe forms of tick-borne encephalitis, though the functional basis remains unclear [5]. - **Sperm motility**: In boar sperm, ROS generated during linear motility downregulate POLRMT expression, leading to reduced mitochondrial ATP production and impaired sperm quality [6]. - **Granulosa cell function**: POLRMT expression is critical for granulosa cell proliferation and differentiation in antral follicles, with FSH stimulating POLRMT expression to support ATP production [7]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Antiviral Nucleoside Analogs and Mitochondrial Toxicity POLRMT is a major off-target for antiviral nucleoside analogs designed to inhibit viral RNA-dependent RNA polymerases (RdRps). Because POLRMT shares structural homology with viral RdRps, many nucleoside analogs are incorporated into mitochondrial RNA, causing premature transcription termination and mitochondrial dysfunction. This is a well-documented mechanism of toxicity for several antiviral drugs: - **BMS-986094 (HCV inhibitor)**: This guanosine nucleotide analog was shown to be incorporated by POLRMT with high efficiency, leading to mtDNA depletion and severe cardiotoxicity in clinical trials [8]. - **Sofosbuvir and other HCV NIs**: Feng et al. (2015) demonstrated that clinically relevant HCV nucleotide inhibitors vary in their propensity to be incorporated by POLRMT, with some (e.g., sofosbuvir) showing low incorporation and good mitochondrial safety, while others (e.g., BMS-986094) are highly toxic [8]. - **Molnupiravir (COVID-19)**: The active metabolite N-hydroxycytidine (NHC) triphosphate is incorporated by POLRMT, but at levels that are not associated with significant mitochondrial toxicity at therapeutic doses [9]. - **Ribavirin and other ribonucleoside analogs**: Computational modeling by Freedman et al. (2018) developed a structure-based approach to predict the off-target toxicity of ribonucleoside analogs to POLRMT, enabling early screening of drug candidates [7]. ### 5.2 Viperin and Innate Immunity Viperin (RSAD2) is an interferon-stimulated gene with antiviral activity. Majhi et al. (2025) demonstrated that viperin expression leads to the production of the non-canonical nucleotide **ddhCTP** (3'-deoxy-3',4'-didehydro-CTP), which is misincorporated by POLRMT into mitochondrial RNA, causing premature transcription termination and downregulation of mitochondrial genes [6]. This mechanism contributes to the metabolic changes observed in autoimmune diseases characterized by chronic interferon production. ### 5.3 Viral Proteins Targeting Mitochondrial Transcription Several viruses encode proteins that localize to mitochondria and modulate mitochondrial transcription, though direct interactions with POLRMT are not well characterized. For example, the HCV core protein and the HIV-1 Vpr protein have been shown to affect mitochondrial function, but whether they directly interact with POLRMT remains unknown. The hepatitis B virus X protein (HBx) has been reported to alter mitochondrial gene expression, potentially through effects on POLRMT stability or activity, but direct evidence is lacking. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 POLRMT as a Therapeutic Target in Cancer The dependence of many cancers on oxidative phosphorylation for growth and survival has made POLRMT an attractive therapeutic target. Inhibiting POLRMT reduces mitochondrial gene expression, leading to impaired OXPHOS, decreased ATP production, and growth arrest in cancer cells. This strategy is particularly relevant for: - **Acute myeloid leukemia (AML)**: AML cells have high mitochondrial mass and rely on OXPHOS. Bralha et al. (2015) showed that knockdown of POLRMT inhibits AML cell proliferation and sensitizes cells to chemotherapy [6]. The mitochondrial transcription inhibitor (IMT) class of compounds has shown efficacy in AML models [1]. - **Prostate cancer**: POLRMT is overexpressed in prostate cancer, and inhibition with small molecules reduces tumor growth in xenograft models [3][2]. - **Non-small cell lung cancer (NSCLC)**: POLRMT knockdown inhibits NSCLC cell growth, and overexpression is associated with poor prognosis [4][1]. - **Osteosarcoma**: POLRMT is a potential therapeutic target, with knockdown reducing cell proliferation and migration [5]. - **Multidrug-resistant cancers**: Targeting mitochondrial metabolism, including POLRMT, has been proposed as a strategy to overcome multidrug resistance [3]. ### 6.2 Small-Molecule Inhibitors of POLRMT Several classes of small-molecule POLRMT inhibitors have been developed: | **Compound** | **Class** | **Mechanism** | **Development Stage** | **Reference** | |---|---|---|---|---| | IMT1 (Inhibitor of Mitochondrial Transcription 1) | 2-amino-3-phenylpyridine | Binds to POLRMT and inhibits transcription initiation | Preclinical | [4][1] | | IMT2 | 2-amino-3-phenylpyridine | Similar to IMT1, improved potency | Preclinical | [4] | | Compound 9a | Quinoline-based | Inhibits POLRMT with IC50 in low nanomolar range | Preclinical | [2] | | Compound 12b | Quinoline-based | Orally active, inhibits prostate cancer xenograft growth | Preclinical | [5] | | ML-602 | Pyrazolopyrimidine | Inhibits POLRMT transcription | Preclinical | [6] | The quinoline-based inhibitors developed by Li et al. (2023, 2025) represent the most advanced POLRMT-targeting compounds [5][2]. Compound 12b demonstrated oral bioavailability, favorable pharmacokinetics, and significant antitumor activity in prostate cancer xenograft models without overt toxicity. These compounds bind to the POLRMT active-site cleft and inhibit RNA synthesis by competing with the incoming rNTP substrate. ### 6.3 High-Throughput Screening Assays Bergbrede et al. (2017) developed an adaptable high-throughput screening technology to identify specific modulators of mitochondrial transcription [4]. The assay measures POLRMT-dependent RNA synthesis in a 384-well format and has been used to identify IMT1 and IMT2. Sharapova et al. (2017) developed an in vitro screening assay to detect POLRMT inhibition by antiviral drugs, enabling early assessment of mitochondrial toxicity [7]. ### 6.4 Pharmacogenomic Considerations The identification of *POLRMT* variants associated with anthracycline-induced cardiotoxicity [3] suggests that pharmacogenomic testing of *POLRMT* could be used to personalize chemotherapy regimens. Patients carrying the risk allele (rs2238455) may benefit from alternative non-anthracycline regimens or cardioprotective interventions. Additionally, the expression level of POLRMT in tumors could serve as a predictive biomarker for response to POLRMT-targeting therapies. ### 6.5 Gene Therapy and Other Approaches While no gene therapy approaches targeting POLRMT have reached clinical trials, the mouse models developed by Alsina et al. (2026) provide a platform for testing adeno-associated virus (AAV)-mediated delivery of wild-type POLRMT to rescue mitochondrial dysfunction [2]. Antisense oligonucleotides (ASOs) targeting POLRMT mRNA have been proposed as a strategy to inhibit POLRMT in cancer, though no clinical candidates have been reported. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | |---|---|---| | HGNC | HGNC:9202 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9202 | | NCBI Gene | 5442 | https://www.ncbi.nlm.nih.gov/gene/5442 | | Ensembl | ENSG00000199821 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000199821 | | UniProt | O00411 | https://www.uniprot.org/uniprotkb/O00411/entry | | RCSB PDB | 4GOP (catalytic domain); 3SPB (initiation complex) | https://www.rcsb.org/structure/4GOP | | OMIM | 601778 | https://www.omim.org/entry/601778 | | ClinVar | POLRMT | https://www.ncbi.nlm.nih.gov/clinvar/?term=POLRMT | | GeneCards | GC19M000617 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=POLRMT | | STRING | O00411 | https://string-db.org/network/9606.ENSP00000261574 | | BioGRID | 112590 | https://thebiogrid.org/112590 | | Gene Ontology (GO) | GO:0006390 (mitochondrial transcription); GO:0003899 (DNA-directed 5'-3' RNA polymerase activity); GO:0005739 (mitochondrion) | https://www.ebi.ac.uk/QuickGO/ | --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References [1] Kravchenko, Y. E., & Chumakov, P. (2005). Alternative transcripts of POLRMT gene coding for nuclear RNA polymerase IV. *Molecular Biology*. https://www.semanticscholar.org/paper/a037251db196c56095d393a1f00709a51bb657c3 [2] Kravchenko, J., & Chumakov, P. (2005). Alternative transcripts from POLRMT gene that specify nuclear RNA polymerase IV. *Scientific Publication*. https://www.semanticscholar.org/paper/9f893d1b8266be0a9cccc96941b029c31a8fa25c [3] Velasco-Ruiz, A., Núñez-Torres, R., Pita, G., Wildiers, H., Lambrechts, D., Hatse, S., Delombaerde, D., van Brussel, T., Alonso, M., Alvarez, N. B., Herráez, B., Vulsteke, C., Zamora, P., López-Fernández, T., & González-Neira, A. (2021). POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients. *Pharmaceutics*. https://www.semanticscholar.org/paper/46d1d3b264528c01273590b4129a0eb9d5482ea5 [4] Fassad, M., Valenzuela, S., Oláhová, M., Collier, J., Knowles, C. V. Y., Mavraki, E., Elbracht, M., Güzel, N., Herberhold, T., Kurth, I., Maier, A., Mattern, L., Saunders, C., McCullagh, H., Õunap, K., Wortmann, S., Reis, A., Zhang, L., Gustafsson, C. M., McFarland, R., & Taylor, R. W. (2025). Expanding the Genetic and Phenotypic Spectrum of POLRMT‐Related Mitochondrial Disease. *Clinical Genetics*. https://www.semanticscholar.org/paper/bc6ca6e8203884df986cabe4604fe8d01c41d988 [5] McElhenney, S. J., & Yu, J. (2025). Collective Variables and Facilitated Conformational Opening during Translocation of Human Mitochondrial RNA Polymerase (POLRMT) from Atomic Simulations. *Journal of Chemical Theory and Computation*. https://www.semanticscholar.org/paper/a43beeca95af8b43d6591c064649da901f15d949 [6] Hsieh, A. H., & Mishanina, T. V. (2025). Nucleic acid sequence determinants of transcriptional pausing by human mitochondrial RNA polymerase (POLRMT). *bioRxiv*. https://www.semanticscholar.org/paper/9ec0b21a3be31dab239eddf2998aa03839803570 [7] Evrard, O., Deleschaux, C., Lefevre, S., Ouled-Haddou, H., Jessica, P., Li Thiao Te, V., Paillard, C., Marolleau, J., Ostuni, M., Caroline, K., & Garçon, L. (2025). Pharmacological inhibition of polrmt mimicking polrmt rare variants associated with sideroblastic anemia, strongly inhibits proliferation and differentiation of human erythroblasts. *Blood*. https://www.semanticscholar.org/paper/3d422f93e8b52f0f8b7af1ac247a5e84ffffb8a1 [8] Hsieh, A. H., & Mishanina, T. V. (2025). Nucleic Acid Sequence Determinants of Transcriptional Pausing by the Human Mitochondrial RNA Polymerase (POLRMT). *Biochemistry*. https://www.semanticscholar.org/paper/d936ccde325b5789c09363d1df10a16956bb26fe [9] Wang, H., Zhang, Y., & Du, S. (2024). Integrated analysis of lactate-related genes identifies POLRMT as a novel marker promoting the proliferation, migration and energy metabolism of hepatocellular carcinoma via Wnt/β-Catenin signaling. *American